Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Systemic Glutathione Level in Normal Tension Glaucoma
This study is not yet open for participant recruitment.
Verified by The Catholic University of Korea, December 2007
Sponsored by: The Catholic University of Korea
Information provided by: The Catholic University of Korea
ClinicalTrials.gov Identifier: NCT00570362
  Purpose

The purpose of this study is to evaluate whether systemic glutathione level is decreased in patients with normal tension glaucoma.


Condition
Normal Tension Glaucoma

Genetics Home Reference related topics: early-onset glaucoma
MedlinePlus related topics: Glaucoma
Drug Information available for: Glutathione
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Cross-Sectional
Official Title: Evaluation of Systemic Glutathione Level in Patients With Normal Tension Glaucoma

Further study details as provided by The Catholic University of Korea:

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

serum


Estimated Enrollment: 60
Study Start Date: March 2008
Estimated Study Completion Date: October 2008
Detailed Description:

Normal tension glaucoma is one of the most common cause of primary open angle glaucoma in Korea. Even though, we still do not know what the cause is. Only IOP-lowering drugs are the currently available therapeutic method. Glutathione is one of the mostly high concentrated intracellular antioxidants. We find apoptosis of neuronal cell in the mouse retina by systemic depletion of glutathione using buthionine sulfoximine. Glutathione is also known to be reduced in primary open angle glaucoma with high IOP. So we are planning to evaluate systemic glutathione level in normal tension glaucoma.

Blood samples will be obtained by venipuncture to the antecubital vein of normal tension glaucoma patients and age-matched normal controls. Five milliliters of blood will be collected in EDTA-treated tubes (to prevent oxidation). Thirty microliters of blood will be then transferred into centrifuge tubes, and will be added 33.3 microliter of 5-sulfosalicylic acid (SSA), 100mg/mL within 10 minutes from the blood collection.Each sample will be then diluted with 936.7 microliter sodium phosphate buffer (pH 7.5), and the content of each tube will be mixed rapidly in a centrifuge at 13,000 rpm for 5 minutes. A portion of supernatant (150 microliter) will be then collected into clean centrifuge tubes and immediately cooled at -70°C. To each well of a 96-well plate, 150 microliter of daily buffer (3 mg NADPH into 10 mL sodium phosphate buffer), 50microliter of DTNB solution, and 25 microliter of standards or samples will be added in quadruplicate, and the plate will be incubated at 37 °C for 3 minutes.Finally, 25 microliter GSSGR will be added to the previous mixture, and the plate will be read at 410 nm using a 96-well plate reader(UV spectrophotometer).

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients of tertiary referred center

Criteria

Inclusion Criteria:

  • Clinical Diagnosis of Normal Tension Glaucoma: Patients underwent diurnal IOP phasing and were diagnosed as having normal tension glaucoma(IOP always lesser than 22 mm Hg by applanation tonometry), glaucomatous optic disc cupping on fundoscopic examination, open anterior chamber angles by gonioscopy(Schaffer grade III or more), and repeatable VF defects consistent with the diagnosis of glaucoma, according to results obtained with program 24-2 of the Humphrey Field Analyzer.
  • Must be able to provide intravenous blood sampling

Exclusion Criteria:

  • Narrow iridocorneal angles
  • Any evidence of secondary open-angle glaucoma
  • Any other ocular disease except cataract
  • History of previous intraocular surgery including cataract
  • Any other systemic disease except hypertension

The control group:

  • Age-matched healthy volunteers who had neither glaucoma nor other ocular diseases such as cataract, DR, or ARMD.

Exclusion criteria for both groups:

  • Smoking
  • History of any chronic systemic disease with presumed low glutathione levels, including autoimmune diseases, alcoholic liver disease, cancer, and diabetes mellitus.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00570362

Locations
Korea, Republic of
College of Medicine, The Catholic University of Korea, St. Mary's Hospital
Seoul, Korea, Republic of, 150-713
Sponsors and Collaborators
The Catholic University of Korea
Investigators
Study Director: Jung-Il Moon, Professor Department of Ophthalmology, St.Mary's Hospital, College of Medicine, The Catholic University of Korea
  More Information

Responsible Party: St.Mary's Hospital, College of Medicine, The Catholic University of Korea ( Jung-Il Moon )
Study ID Numbers: Merck-001, CMCEYE-GSH
Study First Received: December 7, 2007
Last Updated: December 7, 2007
ClinicalTrials.gov Identifier: NCT00570362  
Health Authority: Korea: Food and Drug Administration

Keywords provided by The Catholic University of Korea:
Normal tension glaucoma
Glutathione
Antioxidant

Study placed in the following topic categories:
Glaucoma
Eye Diseases
Hypertension
Ocular Hypertension

ClinicalTrials.gov processed this record on January 13, 2009